



Optimizing Outcomes for Patients With DOAC-Related Bleeding:



A Multidisciplinary Appraisal of Data-Driven
Management Strategies Using Specific Reversal Agents



Cornerstone
Medical
Education

AA[®]CME[®]
AMERICAN ACADEMY OF CME, INC.

Presented by Cornerstone Medical Education, LLC
Supported by an independent educational grant from AstraZeneca

Bibliography & Suggested Reading

Ansell JE, Bakhru S, Lalicich BE, Tracey G, Villano S, Freedman D. Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects. *Eur Heart J*. 2022;43(10):985-992.

Ansell JE, Bakhru SH, Lalicich BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. *N Engl J Med*. 2014;371(22):2141-2142.

Ansell JE, Lalicich BE, Bakhru SH, et al. Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants. *Blood*. 2021;137(1):115-125.

Ansell JE, Lalicich BE, Bakhru SH, Hoffman M, Steiner SS, Costin JC. Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. *Thromb Res*. 2016;146:113-118.



Ansell JE. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. *J Thromb Thrombolysis*. 2016;41(2):248-252.

Arbel R, Sergienko R, Hammerman A, et al. Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation. *Am J Med*. 2019;132(7):847-855.e3.

AstraZeneca Press Release. Andexanet alfa phase IV trial stopped early after achieving pre-specified criteria on hemostatic efficacy versus usual care. June 5, 2023. Available at: <https://www.astrazeneca.com/media-centre/press-releases/2023/andexxa-phase-iv-trial-stopped-early-after-achieving-pre-specified-criteria-on-haemostatic-efficacy-versus-usual-care.html>. Accessed February 2024.

Baugh CW, Levine M, Cornutt D, et al. Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. *Ann Emerg Med*. 2020;76(4):470-485.

Budnitz DS, Shehab N, Lovegrove MC, Geller AI, Lind JN, Pollock DA. US Emergency Department Visits Attributed to Medication Harms, 2017-2019. *JAMA*. 2021;326(13):1299-1309.

Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. *Heart*. 2017;103(4):307-314.

Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. *J Thromb Haemost*. 2015;13(11):2012-2020.

Chang SH, Chou IJ, Yeh YH, et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. *JAMA*. 2017;318(13):1250-1259.

Cision PR Newswire. FDA provides full approval to idarucizumab, specific reversal agent for dabigatran. April 17, 2018. Available at: <https://www.prnewswire.com/news-releases/fda-provides-full-approval-to-praxbind-specific-reversal-agent-for-pradaxa-300631175.html>. Accessed February 2024.

Connolly S. *World Stroke Congress*. Plenary Presentation – ANNEXA-I. October 10-12, 2023. Toronto, Ontario, Canada.

Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. *N Engl J Med*. 2019;380(14):1326-1335.

Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. *N Engl J Med*. 2016;375(12):1131-1141.

Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. *Am J Hematol*. 2019;94(6):697-709.



den Exter PL, Woller SC, Robert-Ebadi H, et al. Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. *J Thromb Haemost.* 2022;20(8):1910-1919.

Dobesh PP, Fermann GJ, Christoph MJ, et al. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study. *Res Pract Thromb Haemost.* 2023;7(6):102192.

Drugs@FDA: FDA-Approved Drugs. Andexanet alfa. May 2022. Available at: <https://www.fda.gov/media/113279/download>. Accessed February 2024.

Drugs@FDA: FDA-Approved Drugs. Idarucizumab. February 11, 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761025s013lbl.pdf. Accessed February 2024.

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. *Circulation.* 2011;124(14):1573-1579.

Eikelboom JW, Connolly SJ, Hart RG, et al. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. *J Am Coll Cardiol.* 2013;62(10):900-908.

Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI. Idarucizumab: The Antidote for Reversal of Dabigatran. *Circulation.* 2015;132(25):2412-2422.

Fanikos J, Murwin D, Gruenenfelder F, et al. Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. *Thromb Haemost.* 2020;120(1):27-35.

FDA Approval Letter. Andexanet alfa. May 3, 2018. Available at: <https://www.fda.gov/media/113285/download?attachment>. Accessed February 2024.

Fralick M, Colacci M, Schneeweiss S, Huybrechts KF, Lin KJ, Gagne JJ. Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study. *Ann Intern Med.* 2020;172(7):463-473.

Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2013;369(22):2093-2104.

Gómez-Outes A, Alcubilla P, Calvo-Rojas G, et al. Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants. *J Am Coll Cardiol.* 2021;77(24):2987-3001.

Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2011;365(11):981-992.



Gunasekaran K, Rajasurya V, Devasahayam J, et al. A Review of the Incidence Diagnosis and Treatment of Spontaneous Hemorrhage in Patients Treated with Direct Oral Anticoagulants. *J Clin Med*. 2020;9(9):2984.

Held C, Hylek EM, Alexander JH, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. *Eur Heart J*. 2015;36(20):1264-1272.

Heo YA. Andexanet Alfa: First Global Approval. *Drugs*. 2018 Jul;78(10):1049-1055. Erratum in: *Drugs*. 2018 Aug;78(12):1285.

Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37(38):2893-2962.

Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. *JAMA*. 2015;313(8):824-836.

Little D, Siegal DM. Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding. *Thromb Res*. 2019;180:86.

Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. *Circulation*. 2013;128(21):2325-2332.

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers [published correction appears in *Thromb Haemost*. 2013 Jan;109(1):169]. *Thromb Haemost*. 2012;108(2):217-224.

Milling TJ Jr, Middeldorp S, Xu L, et al. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. *Circulation*. 2023;147(13):1026-1038.

Milling TJ, Pollack CV. A review of guidelines on anticoagulation reversal across different clinical scenarios - Is there a general consensus?. *Am J Emerg Med*. 2020;38(9):1890-1903.

Panos NG, Cook AM, John S, Jones GM; Neurocritical Care Society (NCS) Pharmacy Study Group. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. *Circulation*. 2020;141(21):1681-1689.

Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011;365(10):883-891.

Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. *N Engl J Med*. 2017;377(5):431-441.



Refaai MA, Bajcic P, McNeill R, et al. Retrospective Analysis of the Real-World Utilization of 4-Factor Prothrombin Complex Concentrate and Plasma in Oral Anticoagulant-Associated Bleeding in US Hospitals. *Clin Appl Thromb Hemost*. 2023;29:10760296231179682.

Ruff CT, Giugliano RP, Antman EM. Management of bleeding with non-vitamin K antagonist oral anticoagulants in the era of specific reversal agents. *Circulation*. 2016;134(3):248-261.

Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet*. 2014;383(9921):955-962.

Sarich TC, Seltzer JH, Berkowitz SD, et al. Novel oral anticoagulants and reversal agents: considerations for clinical development. *Am Heart J*. 2015;169(6):751-757.

Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. *Blood*. 2013;121(18):3554-3562.

Selak V, Kerr A, Poppe K, et al. Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy. *JAMA*. 2018;319(24):2507-2520.

Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. *N Engl J Med*. 2015;373(25):2413-2424.

Steinberg BA, Shrader P, Thomas L, et al. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. *J Am Coll Cardiol*. 2016;68(24):2597-2604.

Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee [published correction appears in *J Am Coll Cardiol*. 2021 Jun 1;77(21):2760]. *J Am Coll Cardiol*. 2020;76(5):594-622.

Troy A, Anderson TS. National Trends in Use of and Spending on Oral Anticoagulants Among US Medicare Beneficiaries From 2011 to 2019. *JAMA Health Forum*. 2021;2(7):e211693.

US National Library of Medicine. ClinicalTrials.gov. Available at: <https://classic.clinicaltrials.gov/>. Accessed February 2024.

van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. *Blood*. 2014;124(12):1968-1975.

van Es N, De Caterina R, Weitz JI. Reversal agents for current and forthcoming direct oral anticoagulants. *Eur Heart J*. 2023;44(20):1795-1806.



van Rein N, Heide-Jørgensen U, Lijfering WM, et al. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. *Circulation* 2019;139:775–786.

Wang K, Li H, Kwong WJ, et al. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. *J Am Heart Assoc.* 2017;6(8):e006703.

WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions [published correction appears in *Lancet Glob Health.* 2023 Feb;11(2):e196]. *Lancet Glob Health.* 2019;7(10):e1332-e1345.

Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. *Blood Adv.* 2018;2(22):3257-3291.

World Health Organization (WHO) website. Cardiovascular diseases (CVDs). June 11, 2021. Available at: [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)). Accessed February 2024.

World Stroke Congress website. Highlights from WSC 2023. Available at: <https://worldstrokecongress.org/highlights-from-wsc-2023/>. Accessed February 2024.